作者：
Dongjune,Kim [1]
;
Rucha,Natu [2]
;
Richard,Malinauskas [2]
;
Jin Hyen,Baek [3]
;
Paul W,Buehler [4]
;
Xin,Feng [5]
;
Haiou,Qu [5]
;
Julia,Pinto [6]
;
Xiaoming,Xu [5]
;
Luke,Herbertson [7]
作者单位：
US FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Silver Spring, MD, United States of America; US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, MD, United States of America.
[1]
US FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Silver Spring, MD, United States of America.
[2]
US FDA, Center for Biologics Evaluation and Research, Division of Blood Components and Devices, Laboratory of Biochemistry and Vascular Biology, Silver Spring, MD, United States of America.
[3]
University of Maryland School of Medicine, Center for Blood Oxygen Transport and Hemostasis and the Department of Pathology, Baltimore, MD, United States of America.
[4]
US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, MD, United States of America.
[5]
US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of New Drug Products, Silver Spring, MD, United States of America.
[6]
US FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Silver Spring, MD, United States of America. Electronic address: luke.herbertson@fda.hhs.gov.
[7]
DOI
10.1016/j.tiv.2024.105793
PMID
38401745
发布时间
2024-04-16
换一批
换一批
